NCT06894251

Effect of LIMICOL®-NG on Plasma LDL-cholesterol Concentration in Subjects with Moderate Hypercholesterolemia

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 35 (estimated)
• Sponsor: Institut Pasteur de Lille · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The goal of this clinical trial is to observe a decrease in plasma LDL cholesterol concentration of 10% (or 0.20g/L) in subjects with untreated moderate hypercholesterolemia after 3 months of consumption of the Limicol®-NG food supplement, compared with a historical placebo group

Detailed description

The objective is to evaluate the effect of the Limicol®-NG food supplement during the 3 months of taking it (after 1 and 3 months of consumption versus T0) and comparison versus placebo history of the evolution over time (from 0 to 3 months) of the following parameters: * Weight, * BMI, * Waist circumference, * Systolic and diastolic blood pressures, * Resting heart rate. * Fasting blood sugar * LDL cholesterol * Non-HDL cholesterol (NHC) * Total cholesterol (TC) * HDL cholesterol * Triglycerides (TG) * LDL/HDL and TC/HDL ratios, * Safety parameters measured from blood samples at VS and V2: ASAT, ALAT, Gamma-GT, Creatine Kinase, Lactate DeHydrogenase, Bilirubin, Creatinine, and Urea.

Conditions

• Healthy Volunteer

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	LIMICOL® NG	All subjects will consume 2 tablets per day during the entire intervention period, i.e. 12 weeks between V0 and V2, distributed as follows: 1 tablet in the morning at the end of or after breakfast (no taking on an empty stomach) and 1 tablet in the evening during dinner. If a dose is missed, 2 tablets can be taken at the next dose.

Timeline

• Start date: 2025-03-10
• Primary completion: 2025-09-30
• Completion: 2025-12-01
• First posted: 2025-03-25
• Last updated: 2025-03-25

Locations

1 site across 1 country: France